ITMI20032528A1 - Uso di cistina o di cisteina per la prevenzione e il - Google Patents

Uso di cistina o di cisteina per la prevenzione e il

Info

Publication number
ITMI20032528A1
ITMI20032528A1 IT002528A ITMI20032528A ITMI20032528A1 IT MI20032528 A1 ITMI20032528 A1 IT MI20032528A1 IT 002528 A IT002528 A IT 002528A IT MI20032528 A ITMI20032528 A IT MI20032528A IT MI20032528 A1 ITMI20032528 A1 IT MI20032528A1
Authority
IT
Italy
Prior art keywords
cystine
cistein
prevention
treatment
cysteine
Prior art date
Application number
IT002528A
Other languages
English (en)
Inventor
Francesco Santangelo
Original Assignee
Francesco Santangelo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Francesco Santangelo filed Critical Francesco Santangelo
Priority to IT002528A priority Critical patent/ITMI20032528A1/it
Priority to PCT/EP2004/014359 priority patent/WO2005058305A1/en
Priority to US10/583,334 priority patent/US8362079B2/en
Priority to CA2551043A priority patent/CA2551043C/en
Priority to DE602004012152T priority patent/DE602004012152T2/de
Priority to ES04803971T priority patent/ES2300856T3/es
Priority to EP04803971A priority patent/EP1696901B1/en
Priority to AT04803971T priority patent/ATE387195T1/de
Priority to MXPA06006778A priority patent/MXPA06006778A/es
Priority to JP2006544341A priority patent/JP5564159B2/ja
Publication of ITMI20032528A1 publication Critical patent/ITMI20032528A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
IT002528A 2003-12-19 2003-12-19 Uso di cistina o di cisteina per la prevenzione e il ITMI20032528A1 (it)

Priority Applications (10)

Application Number Priority Date Filing Date Title
IT002528A ITMI20032528A1 (it) 2003-12-19 2003-12-19 Uso di cistina o di cisteina per la prevenzione e il
PCT/EP2004/014359 WO2005058305A1 (en) 2003-12-19 2004-12-16 The use of cystine or cysteine for the prevention and treatment of oxidative stress caused by haemodialysis and of acute or chronic kidney diseases
US10/583,334 US8362079B2 (en) 2003-12-19 2004-12-16 Method for treating hemodialysis-related oxidative stress using cystine or cysteine
CA2551043A CA2551043C (en) 2003-12-19 2004-12-16 The use of cystine or cysteine for the prevention and treatment of oxidative stress caused by haemodialysis and of acute or chronic kidney diseases
DE602004012152T DE602004012152T2 (de) 2003-12-19 2004-12-16 Verwendung von cystin oder cystein zur vorbeugung und behandlung von oxidativem stress hervorgerufen durch hämodialyse bei patienten mit chronischen nierenerkrankungen
ES04803971T ES2300856T3 (es) 2003-12-19 2004-12-16 El uso de cistina o cisteina para la prevencion y el tratamiento de estres oxidativo provocado por hemodialisis en pacientes con enfermedad renal aguda o cronica.
EP04803971A EP1696901B1 (en) 2003-12-19 2004-12-16 The use of cystine or cysteine for the prevention and treatment of oxidative stress caused by haemodialysis in patients with chronic kidney diseases
AT04803971T ATE387195T1 (de) 2003-12-19 2004-12-16 Verwendung von cystin oder cystein zur vorbeugung und behandlung von oxidativem stress hervorgerufen durch hämodialyse bei patienten mit chronischen nierenerkrankungen
MXPA06006778A MXPA06006778A (es) 2003-12-19 2004-12-16 El uso de cistina o cisteina para la prevencion y tratamiento de tension oxidativa ocasionada por hemodialisis y de enfermedades renales agudas o cronicas.
JP2006544341A JP5564159B2 (ja) 2003-12-19 2004-12-16 血液透析から生じる酸化ストレスおよび急性または慢性腎疾患の予防および治療を目的としたシスチンまたはシステインの使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT002528A ITMI20032528A1 (it) 2003-12-19 2003-12-19 Uso di cistina o di cisteina per la prevenzione e il

Publications (1)

Publication Number Publication Date
ITMI20032528A1 true ITMI20032528A1 (it) 2005-06-20

Family

ID=34685626

Family Applications (1)

Application Number Title Priority Date Filing Date
IT002528A ITMI20032528A1 (it) 2003-12-19 2003-12-19 Uso di cistina o di cisteina per la prevenzione e il

Country Status (10)

Country Link
US (1) US8362079B2 (it)
EP (1) EP1696901B1 (it)
JP (1) JP5564159B2 (it)
AT (1) ATE387195T1 (it)
CA (1) CA2551043C (it)
DE (1) DE602004012152T2 (it)
ES (1) ES2300856T3 (it)
IT (1) ITMI20032528A1 (it)
MX (1) MXPA06006778A (it)
WO (1) WO2005058305A1 (it)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20060206A1 (it) * 2006-04-10 2007-10-11 Bio3 Res Srl Composizione farmaceutica orale contenente cistina o cisteina con glutatione per la prevenzione ed il trattamento dello stress ossidativo da emodialisi e dispositivo medico di somministrazione
PL2638915T3 (pl) * 2008-07-18 2017-04-28 A1M Pharma Ab Medyczne zastosowanie zmiatacza wolnych rodników i antyoksydantu alfa-1-mikroglobuliny
UA116639C2 (uk) * 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
ES2521841B1 (es) * 2013-05-08 2015-09-09 Instituto De Investigación Sanitaria - Fundación Jiménez Díaz Procedimiento de diagnóstico y pronóstico de la enfermedad renal crónica en un sujeto humano
JP6906807B2 (ja) 2018-08-31 2021-07-21 一般社団法人クラインシュタイン医工学パースペクティブ 透析装置

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334617A (en) * 1984-03-19 1994-08-02 The Rockefeller University Amino acids useful as inhibitors of the advanced glycosylation of proteins
DE3414491A1 (de) * 1984-04-17 1985-10-24 Hans Dr. 8202 Bad Aibling Dietl L-aminosaeurengemische fuer die parenterale und orale anwendung bei nierenerkrankungen
DE3445253A1 (de) 1984-12-12 1986-06-26 Dr. Madaus & Co, 5000 Köln Nephrologisch-urologisches arzneimittel
JPH0610132B2 (ja) * 1985-11-27 1994-02-09 千寿製薬株式会社 糖尿病性白内障治療薬
JPH0667831B2 (ja) 1986-01-13 1994-08-31 森永乳業株式会社 肝物質合成機能障害改善用のアミノ酸組成物
CA1339256C (en) * 1989-01-26 1997-08-12 Wulf Droge Treatment of diseases associated with hiv-infections
JPH02212424A (ja) * 1989-02-10 1990-08-23 Toutoushiyu Seizo Kk 肝障害抑制剤
JP2534139B2 (ja) * 1989-10-09 1996-09-11 株式会社大塚製薬工場 腎不全用経口アミノ酸製剤
DE4343593C2 (de) * 1993-12-21 1998-05-20 Asta Medica Ag Verwendung von R-(+)-alpha-Liponsäure, R-(-)-Dihydroliponsäure oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung kompensierter und dekompensierter Insulinresistenz
US5576287A (en) * 1994-04-29 1996-11-19 Wake Forest University Method for treating acute renal disease and failure
NZ527924A (en) 1999-01-29 2005-01-28 Mars Uk Ltd Antioxidant compositions and methods for companion animals
IT1312377B1 (it) * 1999-03-05 2002-04-15 Uni Ci S R L Composizioni a base di acido tiottico, cisteina e/o n-acetil cisteinada utilizzarsi in preparazioni farmaceutiche, dietetiche e cosmetiche
IT1312086B1 (it) * 1999-04-21 2002-04-04 Zambon Spa Uso della nac per la preparazione di un medicamento adatto allasomministrazione endovenosa per la prevenzione dello stress
JP2004521083A (ja) * 2000-10-27 2004-07-15 ニトロメッド，インク． 酸化窒素不足によって特徴づけられる血管疾患の治療方法
US20020137785A1 (en) * 2001-03-26 2002-09-26 George Kindness Inflammatory mechanism modulator composition and methods with anti-asthmatic properties
FR2826868B1 (fr) * 2001-07-04 2007-10-12 Sanofi Synthelabo Composition pour l'hygiene bucco-dentaire comprenant un vecteur d'ions fluorure et un agent antioxydant, ses utilisations notamment pour l'hygiene bucco-dentaire des sujets diabetiques

Also Published As

Publication number Publication date
ATE387195T1 (de) 2008-03-15
CA2551043A1 (en) 2005-06-30
US20070270495A1 (en) 2007-11-22
JP5564159B2 (ja) 2014-07-30
ES2300856T3 (es) 2008-06-16
MXPA06006778A (es) 2007-01-26
CA2551043C (en) 2012-11-06
EP1696901A1 (en) 2006-09-06
DE602004012152D1 (de) 2008-04-10
EP1696901B1 (en) 2008-02-27
WO2005058305A1 (en) 2005-06-30
JP2007534646A (ja) 2007-11-29
US8362079B2 (en) 2013-01-29
DE602004012152T2 (de) 2009-02-26

Similar Documents

Publication Publication Date Title
CY1105082T1 (el) Χρηση της φλιβανσepινης στην αγωγη διαταραχων της σεξουαλικης επιθυμιας
EA200800762A1 (ru) Предотвращение гипотензии и стабилизация кровяного давления у гемодиализных пациентов
EA200701205A1 (ru) Использование полиоксипропилентерпеновых и полиоксиэтилентерпеновых соединений в эмульсионной полимеризации
RS53128B (en) Extending the time of disease progression or survival in patients with ovarian cancers using PERTUZUMAB
EP2324871A3 (en) Citrate anticoagulation system for extracorporeal blood treatments
SE0401253L (sv) Bärbar anordning för kontinuerlig venovenös hemofiltration/dialys
DK1465688T3 (da) Bicarbonat-baserede opløsninger til dialyseterapi
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
NO20050902L (no) Tetrapropylammoniumtetratiomolybdat og beslektede forbindelser for anti-angiogene terapier
HRP20110969T1 (en) Pimobendan to be used for the reduction of heart size in mammals suffering from heart failure
EA200700273A1 (ru) Способ лечения гиперфосфатемии c использованием гидроксикарбоната лантана
BRPI0408198A (pt) processo para tratar e prevenir hiperparatireoidismo com compostos de vitamina d2 ou d4
BRPI0612840A8 (pt) Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções
DK1497330T3 (da) Antagonister af faktor-VIII-interaktion med lav-densitets- lipoproteinreceptor-relateret protein
EA200801274A1 (ru) Лечение субъектов с хронической почечной недостаточностью ( хпн ) с применением соединений лантана
ATE499939T1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
UY28344A1 (es) Nuevos compuestos
HK1097762A1 (en) Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients
DK1643999T3 (da) Pyridoxamin til anvendelse ved behandlingen af diabetisk nefropati ved type 2-diabetes
ITMI20032528A1 (it) Uso di cistina o di cisteina per la prevenzione e il
DK1255569T3 (da) Pax2 til behandling af nyresygdomme
CL2004000984A1 (es) Forma de dosificacion oral de una sal de magnesio de (s)-pantopazol, para la profilaxis o tratamiento de una condicion asociada a inhibir la bomba protonica.
SE0200198D0 (sv) New use
EA200501565A1 (ru) Предназначенная для перорального приёма лекарственная форма для антагонистов протонного насоса
UA85548C2 (ru) Применение водного экстракта листьев красного винограда для предупреждения перехода от клинически незначительных ранних стадий хронической венозной недостаточности к i, ii или iii стадии